ARTICLES BY LOUIS

• A Future Renaissance At Catalent? Employees Think So

  2/8/2024

  Re Monday's news of the purchase of Catalent by Novo Holdings, the seminal question we needed a more definitive answer to is: What specifically is planned for Catalent as a CDMO? Chief Editor Louis Garguilo got some answers. “Customers have been calling me continuously,” said one Catalent executive he spoke with. 

• Novo Holdings Acquires Catalent, Shakes Up Outsourcing World

  2/5/2024

  News of Novo Holdings acquiring Catalent, and Novo Nordisk taking in 3 Catalent fill-finish facilities, shakes up the outsourcing industry at a time when so many biopharma sponsors for already starved for capacity. Here's breaking analysis from chief editor Louis Garguilo.

• Creative Outsourcing Strategies, But Fill-Finish Still A Concern

  2/5/2024

  Chief Editor Louis Garguilo wraps up his discussions with Thomas Rademacher, CEO, Emergex Vaccines, focusing on strategies that mix internal capacity, facility purchases, CDMOs, new technologies, and challenges with fill-finish outsourcing.

• Beyond (And Better Than) mRNA: T Cell Vaccines

  2/1/2024

  During an extraordinary discussion with a historic biotech entrepreneur, he matter-of-factly interjects, “We’re leaving mRNA vaccines in the dust and moving onto a different approach to vaccines.” That ‘dust-generating’ approach is a proprietary T cell-based platform. And it has COVID and many other implications.

• Creating T Cell Vaccines In The Sands

  1/25/2024

  Like others, Saudi Arabia has been dependent on vaccines supply from abroad. That’s about to change. According to the CEO of Emergex, the Saudis intend to produce a new generation of vaccines – predominantly based on "T cell priming, the next step beyond mRNA vaccines.”

• Vaccine Manufacture From The U.K. to Brazil And Saudi Arabia

  1/22/2024

  Why is Professor Thomas Rademacher’s U.K-based vaccine-creating biotech so important that Saudi Arabia has based the establishment of the Kingdom’s first vaccine manufacturing facility on the company? The narrative starts in Brazil.

• Reinventing The Classic Pharma Campus

  1/15/2024

  Perhaps your company is located on, or considering expanding to, a biopharma or life-sciences campus. Ever wonder how these “campuses” (or “parks”) materialize? Jason Benson of JLL Life Sciences Real Estate Solutions explains to chief editor Louis Garguilo.

• Technical Talent Tailing Off At CDMOs?

  1/11/2024

  “Having been outsourcing to CDMOs for 20 years in the small-molecule space, I see a distinct difference in technical performance compared to my mid-2000s CDMOs," says an executive. What's going on here?

• Development And Commercial: 2 Supply Chains For An Ideal Future

  1/5/2024

  How do you transition a supply chain utilized for your development stages to a robust commercial supply chain? Thierry Bilbault knows how. He does done it before, and is at it again. He shares his strategies and secrets.

• 2024: An Outsourcing Future of Information Sharing

  1/3/2024

  I'm a big believer in open-source information as much as possible,” says Nana Collett. “Companies need proprietary information, but I'm a bit radical this way. I believe that as an ecosystem, we're going to get stronger if we can find our way to more data-sharing.”